Catastrophic antiphospholipid syndrome: How to diagnose a rare but highly fatal disease

Therapeutic Advances in Musculoskeletal Disease

Volumn 5, Issue 6, 2013, Pages 305-314

  Aguiar, Cassyanne L ^a   Erkan, Doruk ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

anti 2 glycoprotein 1 antibody; anticardiolipin antibody; antiphospholipid syndrome; catastrophic antiphospholipid syndrome; lupus anticoagulant; thrombosis

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MICROTHROMBUS; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; SEPSIS; THROMBOCYTOPENIA; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 84888231511     PISSN: 1759720X     EISSN: 17597218     Source Type: Journal    
DOI: 10.1177/1759720X13502919     Document Type: Review

References (43)

1. Alpert D. Mandl L. Erkan D. Yin W. Peerschke E. Salmon J. (2008) Anti-heparin platelet factor 4 antibodies in systemic lupus erythematosus are associated with IgM antiphospholipid antibodies and the antiphospholipid syndrome. Ann Rheum Dis 67: 395–401.
2. Asherson R. (2006) New subsets of the antiphospholipid syndrome in 2006: “PRE-APS” (probable APS) and microangiopathic antiphospholipid syndromes (“MAPS”). Autoimmun Rev 6: 76–80.
3. Asherson R. Cervera R. (2008) Microvascular and microangiopathic antiphospholipid-associated syndromes (“MAPS”) semantic or antisemantic? Autoimmun Rev 7: 164–167.
4. Asherson R. Cervera R. de Groot P. Erkan D. Boffa M. Piette J. et al. (2003) Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 12: 530–534.
5. Asherson R. Pierangeli S. Cervera R. (2007) Microangiopathic antiphospholipid associated syndromes revisited new concepts relating to antiphospholipid antibodies and syndromes. J Rheumatol 34: 1793–1795.
6. Avcin T. Toplak N. (2007) Antiphospholipid antibodies in response to infection. Curr Rheumatol Rep 9: 212–218.
7. Bayraktar U. Erkan D. Bucciarelli S. Espinosa G. Cervera R. Asherson R. (2007) Catastrophic antiphospholipid syndrome (CAPS): comparison between CAPS patients with and without thrombocytopenia. Clin Exp Rheumatol 25: 14.
8. Cervera R. (2010 a) Update on the diagnosis, treatment, and prognosis of the catastrophic antiphospholipid syndrome. Curr Rheumatol Rep 12: 70–76.
9. Cervera R. on behalf of CAPS Registry Project Group (2010 b) Catastrophic antiphospholipid syndrome (CAPS): update from the ‘CAPS Registry’. Lupus 19: 412–418.
10. Cervera R. (2012) CAPS Registry. Lupus 21: 755–757
11. Cervera R. Asherson R. (2004) Multiorgan failure due to rapid occlusive vascular disease in antiphospholipid syndrome: the ‘catastrophic’ antiphospholipid syndrome. APLAR J Rheumatol 7: 254–262.
12. Cervera R. Bucciarelli S. Plasin M. Gomez-Puerta J. Plaza J. Guillermo P. et al. for the CAPS Registry Project Group (2009) Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmunity 32: 240–245.
13. Cervera R. Font J. Gomez-Puerta A. Espinosa G. Cucho M. Bucciarelli S. et al. for CAPS Registry Project Group (2005) Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 64: 1205–1209
14. Drenkard C. Sanchez-Guerrero J. Alarcon-Segovia D. (1989) Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol 16: 614–617.
15. Erkan D. (2006) Therapeutic and prognostic considerations in catastrophic antiphospholipid syndrome. Autoimmun Rev 6: 98–103.
16. Erkan D. Espinosa G. Cervera R. (2010) Catastrophic antiphospholipid syndrome: updated diagnostic algorithms. Autoimmun Rev 10: 74–79.
17. Erkan D. Lockshin M. (2012) High risk antiphospholipid antibody profile: matter of the number or titer of tests? E-letter to the editor (re: Incidence of first thrombembolic event in asymptomatic carries of high-risk aPL profile: a multicenter prospective study, Pengo et al. Blood 2011;17:4714), Published online on 24 January 2012, available at: http://bloodjournal.hematologylibrary.org/letters.
18. Erkan D. Yazici Y. Lockshin M. (2002 a) Catastrophic antiphospholipid syndrome (CAPS) or antiphospholipid syndrome (APS) with a catastrophic event? Lupus 11: 617.
19. Erkan D. Yazici Y. Peterson M. Sammaritano L. Lockshin M. (2002 b) A crosssectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome. Rheumatology 41: 924–929.
20. Galli M. Luciani D. Bertolini G. Barbui T. (2003) Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 101: 1827–1832.
21. George D. Vasanth L. Erkan D. Bass A. Salmon J. Lockshin M. (2007) Primary antiphospholipid syndrome presenting as HELLP syndrome. Hosp Special Surg J 3: 216–221.
22. Giron-Gonzalez J. Garcia del Rio E. Rodriguez C. Rodriguez-Martorell J. Serrano A. (2004) Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31: 1560–1567.
23. Hansen K. Kong D. Moore K. Ortel T. (2001) Risk factors associated with thrombosis in patients with antiphospholipid antibodies. J Rheumatol 28: 2018–2024.
24. Hudson M. Herr A.L. Rauch J. Neville C. Chang E. Ibrahim R. et al. (2003) The presence of multiple prothrombotic risk factors is associated with a higher risk of thrombosis in individuals with anticardiolipin antibodies. J Rheumatol 30: 2385–2391.
25. Kaul M. Erkan D. Sammaritano L. Lockshin M. (2007) Assessment of the 2006 revised antiphospholipid syndrome classification criteria. Ann Rheumat Dis 66: 927–930.
26. Kim S. Moskowitz N. Dicarlo E. Bass A. Erkan D. Lockshin M. (2009) Catastrophic antiphospholipid syndrome triggered by sepsis. Hosp Special Surg J 5: 67–72.
27. Kitchens C. Erkan D. Brandao L. Hahn S. James A. Kulkarni R. et al. (2011) Thrombotic storm revisited: preliminary diagnostic criteria suggested by the Thrombotic Storm Study Group. Am J Med 124: 290–296.
28. Kumar S. Papalardo E. Sunkureddi P. Najam S. Gonazlez E. Pierangeli S. (2009) Isolated elevation of IgA anti-Beta2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients. Lupus 18: 1011–1014.
29. Levy M. Fink M. Marshall J. Abraham E. Angus D. Cook D. et al. (2003) 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 31: 1250–1256.
30. Manco-Johnson M. Wang M. Goldenberg N. Soep J. Gibson E. Knoll C. et al. (2012) Treatment, survival, and thromboembolic outcomes of thrombotic storm in children. J Pediatrics 161: 682–688.
31. Miret C. Cervera R. Reverter J. Garcia-Carrasco M. Ramos M. Molla M. et al. (1997) Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic event: transient ‘seronegative’ antiphospholipid syndrome? Clin Exp Rheumatol 15: 541–544.
32. Miyakis S. Lockshin M. Atsumi T. Branch D. Brey R. Cervera R. et al. (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4: 295–306.
33. Ortel T. Kitchens C. Erkan D. Brandao L. Hahn S. James A. et al. (2012) Clinical causes and treatment of the thrombotic storm. Exp Rev Hematol 5: 653–659.
34. Pauzner R. Greinacher A. Selleng K. Althaus K. Shenkman B. Seligsohn U. (2009) False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost 7: 1070–1074.
35. Pengo V. Biasiolo A. Gresele P. Marongiu F. Erba N. Veschi F. et al. (2007) Survey of lupus anticoagulant diagnosis by central evaluation of positive plasma samples. J Thromb Haemost 5: 925–930.
36. Pengo V. Ruffatti A. Legnani C. Testa S. Fierro T. Marongiu F. et al. (2011) Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 118: 4714–4718.
37. Pengo V. Tripodi A. Reber G. Rand J. Ortel T. Galli M. et al. (2009) Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 7: 1737–1740.
38. Rosendaal F. Siscovick D. Schwartz S. Beverly R. Psaty B. Longstreth W. Jr et al. (1997) Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women. Blood 89: 2817–2821.
39. Samarkos M. Davies K. Gordon C. Loizou S. (2006) Clinical significance of IgA anticardiolipin and anti-beta2-GP1 antibodies in patients with systemic lupus erythematosus and primary antiphospholipid syndrome. Clin Rheumatol 25: 199–204.
40. Shah A. Higgins J. Chakravarty E. (2007) Thrombotic microangiopathy hemolytic anemia in a patient with SLE: diagnostic difficulties. Nat Clin Pract Rheumatol 3: 357–362.
41. Vora S. Asherson R. Erkan D. (2006) Catastrophic antiphospholipid syndrome. J Intensive Care Med 21: 144–159
42. Wenzel C. Stoiser B. Locker G. Laczika K. Quehenberger P. Kapiotis S. et al. (2002) Frequent development of lupus anticoagulants in critically ill patients treated under intensive care conditions. Crit Care Med 30: 763–770.
43. Wilson W. Gharavi A. Koike T. Lockshin M. Branch D. Piette J. et al. (1999) International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: report of an international workshop. Arthritis Rheum 42: 1309–1311.